Corona Remedies and Wakefit Innovations are set to list amid divergent grey market signals. Corona Remedies commands strong listing expectations backed by robust subscriptions and profitability, while Wakefit’s muted GMP reflects cautious sentiment towards consumer-facing growth businesses, highlighting current investor preference for earnings visibility and consistency.